PF-04991532
产品说明书
 |
同义名 : | - |
| CAS号 : | 1215197-37-7 | |
| 货号 : | A891536 | |
| 分子式 : | C18H19F3N4O3 | |
| 纯度 : | 99% | |
| 分子量 : | 396.36 | |
| MDL号 : | MFCD27938256 | |
| 存储条件： |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 120 mg/mL(302.75 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
| 生物活性 | |||
|---|---|---|---|
| 描述 | PF-04991532 is a potent, hepatoselective glucokinase activator with EC50s of 80 and 100 nM in human and rat, respectively. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01369602 | Type 2 Diabetes Mellitus ... 展开 >> Healthy 收起 << | Phase 1 | Completed | - | United States, California ... 展开 >> Pfizer Investigational Site Anaheim, California, United States, 92801 United States, Florida Pfizer Investigational Site DeLand, Florida, United States, 32720 收起 << |
| NCT01338870 | Diabetes Mellitus, Type 2 | Phase 2 | Completed | - | - |
| NCT01388829 | Healthy | Phase 1 | Completed | - | United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.52mL 0.50mL 0.25mL |
12.61mL 2.52mL 1.26mL |
25.23mL 5.05mL 2.52mL |
